Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib + cadonilimab
- Development stage
- Phase 1
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Donafenib + cadonilimab is a combination therapy being investigated for the treatment of advanced hepatocellular carcinoma (HCC). Donafenib is an orally administered multi-kinase inhibitor that targets the vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and the Raf/MEK/ERK signaling pathway, thereby exerting anti-angiogenic and anti-proliferative effects. Cadonilimab (AK104) is a first-in-class humanized bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), providing dual immune checkpoint blockade. The combination is designed to synergistically enhance anti-tumor activity by combining the tumor microenvironment modulation of a kinase inhibitor with the potent immune activation of a bispecific checkpoint inhibitor. Clinical development is being led by institutions such as The Sixth Affiliated Hospital of Sun Yat-sen University in collaboration with the drug developers Suzhou Zelgen Biopharmaceuticals and Akeso Biopharma.
- Brand names
- ZepdonKaitani
- Other names
- donafenib + cardunilimabdonafenib plus cadonilimabAK104 + donafenib
02
Targets
BRAF V600ECTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on donafenib + cadonilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib + cadonilimab.